XML 64 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue recognition - Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2017
USD ($)
Nov. 30, 2014
USD ($)
Jan. 31, 2014
USD ($)
Nov. 30, 2011
USD ($)
compound
Jun. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
deliverable
segment
Jun. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
deliverable
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Contract with customer, liability         $ 10,540,000 $ 10,540,000   $ 11,891,000
Number of operating segments | segment           1    
Net product revenue         68,170,000 $ 124,151,000    
Upfront cash payment           2,586,000    
Licensing And Collaboration Agreement                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Upfront cash payment       $ 30,000,000        
Revenue recognition, milestone method, revenue recognized $ 20,000,000 $ 10,000,000 $ 7,500,000          
Revenues           100,000 $ 100,000  
Licensing And Collaboration Agreement | Research And Development Event Milestones                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Revenue recognition, milestone, potential achievements           135,000,000    
Licensing And Collaboration Agreement | Sales Milestones                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Revenue recognition, milestone, potential achievements           325,000,000    
Discovery Agreements                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Revenues           0 0  
Early Stage Collaborations                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Revenues           0 $ 0  
Early Stage Collaborations | Research And Development Event Milestones                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Revenue recognition, milestone, potential achievements           143,000,000    
Early Stage Collaborations | Sales Milestones                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Revenue recognition, milestone, potential achievements           252,000,000    
United States                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Net product revenue         20,300,000 39,500,000    
Non-US                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Net product revenue         $ 47,800,000 $ 84,600,000    
Collaborative Arrangement | Roche And Sma Foundation                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Number of compounds in preclinical development | compound       3        
Number of significant deliverables | deliverable               2
Collaboration And Discovery Agreements                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Number of significant deliverables | deliverable           2    
Minimum | Collaboration And Discovery Agreements                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Collaborative arrangements research period for applying discovery technology           3 years    
Maximum | Collaboration And Discovery Agreements                
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]                
Collaborative arrangements research period for applying discovery technology           4 years